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ABSTRACT 
Separate groups of rats were trained to discriminate the 
narcotic agonist-antagonist, cyclazocine (1.25 mg/kg), from 
saline or the pure narcotic agonist, morphine (10 mg/kg), 
from saline. In the cyclazocine discriminating animals, 
the interoceptive stimuli produced by cyclazocine were found 
to be dose related and largely based on central opiate sys-
tems in that these effects were reversed by the narcotic an-
tagonist, naloxone. The discriminative stimulus produced by 
cyclazocine was found to be completely generalized to nalor-
phine, ethylketocyclazocine, pentazocine and morphine while 
a lesser degree of generalization was seen to the experi-
mental compounds, U-49,274A and U-50,788E. The cyclazocine 
discriminative stimulus did not generalize to apomorphine, 
d-amphetamine, haloperidol, d-butaclamol, 1-butaclamol, clon-
idine, desipramine, amitriptyline, aceperone and butorphanol. 
Cyclazocine generalization to morphine was completely antago-
nized by naloxone at a dose one-twentieth that required to 
antagonize the cyclazocine discriminative stimulus itself. 
At no dose tested did naloxone completely antagonize cycla-
zocine generalization to nalorphine. A possible dopaminergic 
component of the cyclazocine discriminative stimulus was 
demonstrated by attenuation of stimulus strength with the 
neuroleptics haloperidol, benperidol and d-butaclamol. 
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The discriminative stimulus produced by morphine was also 
found to be a dose related effect based upon central opiate 
mechanisms as demonstrated by naloxone reversibility. The 
discriminative stimulus produced by morphine only partially 
generalized to cyclazocine and ethylketocyclazocine. Nalox-
one antagonized the generalization of morphine to cyclazo-
cine but at a dose four times that required to antagonize 
the morphine discriminative stimulus itself. A possible dop-
aminergic component of the morphine discriminative stimulus 
was demonstrated by haloperidol attenuation of stimulus 
strength. 
Cyclazocine analgesia, demonstrated using the mouse tail 
flick procedure, was found to be maximal approximately five 
minutes following cyclazocine administration. Some analge-
sic potency was also ~easurable 35 minutes post cyclazocine. 
The analgesic effects of cyclazocine were found to be re-
versed by naloxone. Pretreatment with the neuroleptics oxi-
peromide, clozapine and dexclamol before cyclazocine was 
found to enhance the analgesic potency of cyclazocine. 
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I. INTRODUCTION 
Cyclazocine is a narcotic agonist-antagonist of the ben-
zomorphan series which was first synthesized in the 1950s as 
part of a search for a nonaddicting narcotic analgesic. Cy-
clazocine possesses narcotic agonistic activity and acts as 
an antagonist to many of the actions of morphine and other 
narcotic agonists. Based on its agonist activity, cyclazo-
cine was considered of substantial clinical potential as an 
analgesic. Early clinical trials revealed that the analge-
sic potency of cyclazocine far surpassed that of morphine in 
post operative patients (Lasagna, et al., 1964). In addition, 
cyclazocine does not produce the euphoria which is observed 
following morphine administration, an effect which is be-
lieved to be the basis of narcotic addiction (Eddy et al., 
1970). As a result, cyclazocine is considered to be of low 
abuse potential (Martin~~ al., 1965). 
Despite these desirable properties, clinical use of cy-
clazocine has been very limited due to the severity of the 
psychotomimetic effects which it produces (Martin~~ al., 
1966; Haertzen, 1970). These effects have been described as 
drunkenness, tiredness, anxiety and hallucinations. The 
neurobiological basis of these effects is unknown. 
In order to experimentally evaLuate the subjective ef-
fects produced by drugs, the behavioral paradigm of drug 
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discrirr.ination has been utilized in which food reinforcement 
is delivered to experimental animals based upon responses 
made on one of two levers. The lever on which responses are 
reinforced is determined by the injection given before re-
sponding commences. Results from such experimentation using 
narcotic drugs has shown that there is a high correlation be-
tween the discriminative properties of these drugs in labor-
atory rats and the subjective effects reported in humans 
(for review see Lal et al., 1977; Colpaert, 1977). 
Recently, cyclazocine has been shown to produce a dis-
criminative stimulus (Hirschhorn, 1977; Rosecrans et al., 
1978; Schaefer and Holtzman, 1978; Teal and Holtzman, 1980); 
however, the mechanism of this action of cyclazocine is un-
known. Further experimentation dealing with the discrimina-
tive stimulus produced by cyclazocine is needed in order 
that the basis of the psychotomimetic effects might be deter-
mined. The present set of experiments was undertaken to in-
vestigate the nature of the discriminative stimulus produced 
by cyclazocine. Animals have been trained to discriminate 
cyclazocine from saline. They were then tested for generali-
zation to selected narcotic agonists, narcotic agonist-antag-
onists and drugs which are known to affect dopaminergic sys-
tems. 
Because of known similarities of characteristics between 
cyclazocine and narcotic agonists, another group of rats was 
trained to discriminate between morphine and saline to pro-
vide critical comparisons. 
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In order to establish that the neuropharmacological ba-
sis of cyclazocine induced discriminative stimuli was dif-
ferent than the analgesic action of cyclazocine, cyclazocine 
induced analgesia was tested in the presence of selected 
neuroleptic drugs. 
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II. LITERATURE SURVEY 
A. Multiple Forms of Opiate Receptors 
Early investigations conducted in the chronic spinal 
dog dealt with blockade of morphine's action with the par-
tial agonist-antagonist, nalorphine and revealed a biphasic 
reversal of morphine activity with increasing doses of nalor-
phine. This lead to speculation that nalorphine was binding 
to a separate opiate receptor in the central nervous system 
(Martin, 1967). Elaboration of these experiments lead to 
the hypothesis that there were three stereochemically related 
opiate receptors, which were designated mu (morphine), kappa 
(ethylketocyclazocine) and sigma (SKF 10,047). Each of these 
receptor types was proposed to have separate spectrums of 
activity when bound by agonists for that particular receptor. 
Occupation of the mu receptor is characterized by miosis, 
bradycardia, hypothermia, depression of nociceptive respon-
ses and indifference to environmental stimuli. Kappa ago-
nists constrict pupils, depress the flexor reflex, and pro-
duce sedation but differs from mu agonists in not altering 
skin twitch or pulse rate. Sigma activity is characterized 
by mydriasis, tachycardia, tachypnea and mania. 
Based on the physiologic responses observed in the 
chronic spinal dog following stimulation of each of these 
receptors, Martin hypothesized the relative role of each 
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receptor in the actions of many narcotic agents (Martin et 
al., 1976). Morphine has been described as having high af-
finity and activity at the mu and kappa receptors while hav-
ing no affinity at the sigma receptor. Cyclazocine, nalor-
phine, pentazocine, oxilorphan and diprenorphine possess 
high affinity but no activity at the mu receptor while hav-
ing moderate to high levels of affinity and activity at the 
kappa and sigma receptors. Similar results have been re-
ported elsewhere (Pickworth and Sharpe, 1979). 
In studies conducted in the rat, the similarity in 
binding and distribution of mu and kappa receptors as well 
as the prevention of new inactivation of these receptors by 
3H-naltrexone and 3H-ethylketocyclazocine has lead to the 
proposal that the kappa receptor may not exist in the rat 
central nervous system (Hiller and Simon, 1979). This re-
port does not dispute the existence of the three receptor 
types in the dog as proposed by Martin. 
In morphine dependent chronic spinal dogs, the adminis-
tration 0£ the pure antagonists naloxone and naltrexone 
precipitated a withdrawal syndrome with the most prominent 
signs being hyperthermia, tachypnea, tachycardia, mydriasis 
and continuous stepping, in that order (Martin et ~l., 1974). 
In chronic spinal dogs made dependent on cyclazocine, simi-
lar challenge with the pure antagonists produced a syndrome 
with the most prominent signs being emesis, tachycardia and 
hyperthermia (Gilbert and Martin, 1976). In these and other 
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experiments, it was found that 20 times as much naltrexone is 
required to precipitate cyclazocine withdrawal as is required 
to precipitate morphine withdrawal (Gilbert and Martin, 1976; 
Pickworth and Sharpe, 1979). 
The abstinence syndrome which emerges four to six hours 
following cessation of morphine administration in the mor-
phine dependent chronic spinal dog is suppressed by morphine 
and d-propoxyphene. Cyclazocine, ethylketocyclazone and keto-
cyclazocine failed to suppress the morphine abstinence with-
drawal syndrome (Martin et al., 1976). In contrast to these 
results, suppression of the abstinence withdrawal in the cy-
clazocine dependent chronic spinal dog was observed follow-
ing the administration of cyclazocine, ethylketocyclazocine, 
ketocyclazocine, pentazocine, morphine and nalorphine (Gilbert 
and Martin, 1976). 
Following chronic administration of N-allylnormetrazo-
cine, a pure sigma agonist, the administration of naltrexone 
or the abrupt withdrawal of drug produced syndromes charac-
terized by enhanced flexor reflex, increased pulse rate and 
decreased rectal temperature. Signs which are commonly ob-
served in the withdrawn rrorphine dependent or cyclazocine 
dependent chronic spinal dog were not observed in the N-al-
lylnormetrazoc ine dependent dog (Martin et al., 1979). 
In addition to the three receptors proposed by Martin, 
a fourth type of receptor, the delta receptor, has been 
proposed based upon the different potencies of naloxone in 
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reversing binding of labeled alkaloids and peptides in the 
guinea pig ileum and mouse vas deferens (Hutchinson et al., 
1975; Lord et al., 1976) and guinea pig brain (Lord et al., 
1977). Results from these experiments indicate that mor-
phine and morphine-like agonists are more potent in the guin-
ea pig ileum, that naloxone readily reverses their effects 
in the guinea pig ileum and mouse vas deferens and that 
these types of agents more readily displace 3H-naloxone, 
3H-naltrexone or 3H-dihydromorphine than 3H-enkephalin 
(Beaumont and Hughes, 1979). The receptors involved have 
been characterized as beinq similar to the mu receptor pro-
posed by Martin (Martin et al., 1976). Conversely, enke-
phalin and enkephalin analogues have been described as delta 
agonists in that their effects are more pronounced in the 
mouse vas deferens, are not readily reversed by naloxone 
and are more efficient in displacing 3H-enkephalins as op-
3 3 posed to H-naloxone or H-naltrexone (Beaurnont and Hughes, 
1979). Beta-endorphin has been found to be equipotent as 
an inhibitor of 3H-enkephalin and 3H-naloxone in the guinea 
pig ileum and mouse vas deferens assays (Lord et al., 1977). 
While it is generally agreed that the mu and delta re-
ceptors exist and that these two receptors show specificity 
for alkaloids and enkephalins, respectively (Lord et al., 
1977; Chang and Cuatracasas, 1979), it has been proposed 
that the differential binding of alkaloid agonist and antag-
onists may be due to changes in the conformation of a single 
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receptor type (Smith and Loh, 1980). Such a proposal stems 
from the demonstration that sodium, added to incubation me-
dium in binding assays, causes a potentiation of narcotic 
antagonist binding (Pert and Snyder, 1974) while also caus-
ing an inhibition of agonist binding (Simon~t~l., 1973). 
Treatment of tissues by the sulfhydryl blocker N-ethyl-
maleimide (NEM) caused a destruction of the opiate receptor 
(Simon et al., 1973; Terenius, 1973). This effect followed 
first order kinetics which suggets that one receptor was 
prevented by agonists, antagonists or pretreatment with so-
dium (Simon and Groth, 1975) . 
B. Clinical Use of Cyclazocine 
Cyclazocine is a narcotic agonist-antagonist of 
the benzomorphan series, the clinical use of which is based 
upon its blockade of opiate receptors in the mammalian cen-
tral nervous system. Cychlazocine has therefore been em-
ployed in maintenance programs for patients physically de-
pendent on narcotics (Chappel et al., 1974; Freedman et al., 
1968; Kleber et al., 1974; Martin et al., 1966; Resnick 
et al., 1974). Cyclazocine itself is considered to be of 
low abuse potential (Martin et al., 1965). 
Acute administration of cyclazocine to naive human sub-
jects produces analgesia, miosis, respiratory depression 
and constipation (Laskowitz et al., 1972), as well as dys-
phoric sensations described as tiredness, moodiness, misery, 
anxiety, hallucinations and drunkenness (Martin et al., 1966; 
Haertzen, 1970). 
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Analgesia following 2 mg of cyclazocine is described as 
being equally if not more potent than 10 mg of morphine. 
Following repeated administration of cyclazocine, tolerance 
develops to the analgesic and subjective effects but toler-
ance to the narcotic antagonistic properties of cyclazocine 
is not observed (Martin et al., 1966). 
--
Chronic administration of cyclazocine results in physi-
cal dependence as evidenced by the observation of an absti-
nence syndrome following abrupt withdrawal of the drug 
(Martin et~!·' 1965). The signs of cyclazocine withdrawal 
include rhinorrhea, lacrimation, hyperthermia and mydriasis. 
While similar signs are observed during morphine withdrawal, 
cyclazocine withdrawal syndrome is considered to be qualita-
tively different from the morphine withdrawal syndrome in 
that the latter includes dramatic increases in blood pres-
sure and respiratory rate while cyclazocine withdrawal showed 
no change in either of these parameters. In addition, cy-
clazocine withdrawal was not associated with drug seeking 
behavior. 
The cyclazocine abstinence syndrome is not detectable 
until four or five days following cessation of drug and 
does not become maximal until the seventh day. Some signs 
of withdrawal persist for as long as six weeks (Martin et 
al., 1965). 
Cyclazocine, administered to subjects physically de-
pendent upon morphine or heroin, precipitates a withdrawal 
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syndrome (Martin, 1965). If, however, the subject is a post 
addict, whose system is "clean" of narcotic agonists, cycla-
zocine administration will not produce a withdrawal syndrome 
nor will it produce euphoria or any effects similar to mor-
phine or heroin, but will prevent the subsequent administra-
tion of these agonists from having any agonistic effects up-
on the subject. This effect of cyclazocine is reported to 
last for 24 hours following a dose of 4 mg. of cyclazocine 
as demonstrated by challenge with 15 mg of heroin I.V. 
(Martin et al., 1966). A similar effect is observed for 72 
hours following a cyclazocine dose of 20 mg. 
The pure narcotic antagonist, naloxone, is equipotent 
with cyclazocine in reversing the effects of morphine. Na-
loxone also antagonizes the pupillary, respiratory depress-
ant, behavioral and subjective effects of cyclazocine 
(Jasinski et al., 1968). Such results would indicate that 
the agonistic and antagonistic activities of cyclazocine 
are mediated at different receptors. 
The dysphoric effects produced by cyclazocine prevented 
its use during early clinical trials (Freedman et al., 1968). 
It was found that these effects could be minimized if a 
treatment induction period of 21 days was employed during 
which the dose of cyclazocine was increased in a gradual 
manner. When naloxone (5 mg/kg) was administered in conjunc-
tion with cyclazocine, so as to minimize the subjective ef-
fects, this induction period could be reduced to four days 
11 
(Resnick, ~~al., 1976). All cyclazocine treatment of post 
addicts was begun 14 days following the last dose of ago-
nist so as to avoid precipitation of withdrawal. 
When cyclazocine was first employed in clinical trials, 
few subjects remained abstinant from opiates for any extended 
period of time. When cyclazocine therapy was conducted si-
multaneously with psychotherapy and counseling, 30% to 60% 
of the patients were opiate free 6 to 27 months following 
initiation of treatment (Resnick et al., 1976; Kleber .~!. ~~., 
1974). After 20 months of treatment, 8.5% of those patients 
only receiving psychotherapy and counseling were opiate free 
(Resnick et al., 1980). 
--
Current research in antagonist therapy for opiate addic-
tion is directed toward the development of antagonists which 
are longer acting than cyclazocine. One aspect of cyclazo-
cine activity which has unexpectedly been considered bene-
ficial in clinical usage, and is being sought in long act-
ing antagonists, is the unpleasant sensations experienced 
upon stopping drug administration. This quality is consid-
ered desirable in treatment of opiate addiction because it 
has been found that patients maintained on cyclazocine were 
less inclined to stop their medication without consulting 
medical personnel first in light of the unpleasant syndrome 
that would emerge. Such encounters between staff and pa-
tient has proven to be of importance in maintaining patients 
on such therapy (Resnick et al., 1980). 
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C. Cyclazocine Analgesia 
Cyclazocine, when administered to human subjects 
suffering from post operative or post partum pain and when 
administered at doses as low as 0.25 mg., produced analgesia 
which was described as equipotent or more potent than 10 mg 
of morphine (Lasagna et al., 1964; Laskowitz, 1972). The 
consistent reports from subjects of the production of se-
vere psychotomimetic effects however, have limited the clini-
cal use of cyclazocine (Lasagna, 1964; Martin et al., 1965; 
Haertzen, 1970). 
Demonstration of cyclazocine analgesia in laboratory 
animals initially proved to be a difficult task. The mouse 
tail flick procedure is a reliable method for demonstrating 
narcotic analgesia (Dewey et al., 1969), but it proved to be 
ineffective in demonstrating cyclazocine analgesia until it 
was shown that the analgesic effects of cyclazocine in lab-
oratory animals reach maximum levels one to five minutes 
following drug administration (Dewey and Harris, 1971). 
Physostigmine, itself being active in the mouse tail 
flick procedure, enhanced the analgesic properties of cycla-
zocine (Harris et al., 1969). 
Increase in adrenergic tone increased the toxicity of 
cyclazocine and other agonist-antagonists but failed to al-
ter the analgesic potency of cyclazocine in the mouse tail 
flick procedure (Dewey et al., 1970). 
Using the mouse tail immersion technique, Sewell and 
Spencer (1975) demonstrated that intracerebroventricular 
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administration of 5-hydroxy tryptamine (10 mg) potentiated 
cyclazocine analgesia while similarly administered noradren-
aline (10 mg) attenuated cyclazocine analgesia. 
Intradermal administration of' ethylenediaminetetraacet-
ic acid (EDTA) in the guinea pig produces a dose dependent 
nociceptive stimulus (Teiger, 1976). Cyclazocine, cyclor-
phan, nalorphine and pentazocine all produced a dose depend-
ent decrease in the nociceptive response (Teiger, 1976). The 
slopes of the dose response curves for the narcotic agonist-
antagoni sts were relatively parallel to the dose response 
curves for other agonist-antagonists but were not parallel 
to the dose response curves for morphine and other narcotic 
agonists in the same analgesic assay. This latter finding 
agrees with previous findings that the narcotic agonist-
antagonists have a different analgesic profile in laboratory 
animals than do morphine and other agonists (Harris and 
Pierson, 1964; Dewey et al., 1970). 
D. Cyclazocine Effects Upon Animal Behavior 
As has been demonstrated in the case of morphine 
(Olds and Travis, 1960), the narcotic agonist-antagonists 
cyclazocine and pentazocine have been shown to produce a 
dose dependent decrease in lateral hypothalamic self-stim-
ulation in the rat (Holtzman, 1976). This effect was dose 
dependently reversed by the narcotic antagonist, naloxone. 
Naloxone at a dose of 1.0 mg/kg produced a 30-fold shift 
to the right of the morphine dose response curve. In the 
/ 
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case of cyclazocine and pentazocine, however, 10 mg/kg nalox-
one produced only a ten-fold shift to the right of the cyclaz-
ocine and pentazocine curves. 
Cyclazocine and pentazocine also produce dose-related 
increases in continuous avoidance behavior and locomotor ac-
tivity in the rat (Holtzman and Jewett, 1972). These effects 
were observed over a dose ·range of 0.125 to 2 mg/kg. Larger 
doses of cyclazocine (4 to 8 mg/kg) were found to disrupt re-
sponding and decrease locomotor activity. Naloxone reverses 
the increase in avoidance behavior produced by cyclazocine 
but is inactive in antagonism of the stimulation of locomo-
tor activity (Holtzman and Jewett, 1973). 
Stimulation of locomotor activity by the narcotic ago-
nist-antagonist pentazocine was reversed by alpha methyl 
paratyrosine, indicating that pentazocine stimulation may be 
mediated by catecholamine release (Holtzman and Jewett, 
1972). Similar experiments have not been conducted with cy-
clazocine. 
The stimulatory effect of cyclazocine upon discriminated 
avoidance responding is preceded by an initial period of re-
sponse inhibition (Wray, 1972). These effects upon avoid-
ance responding were shown to be strikingly similar to the 
effects o f LSD upon similar type behavior leading to specula-
tion by the author that these agents may be acting through 
similar central mechanism. 
In an investigation of drug effects upon behavior con-
trolled by interresponse time (DRL), d,l cyclazocine at doses 
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of 3 and 5.6 mg/kg produced substantial increases in response 
rate with concomitant decreases in number of reinforcements 
received. A dose of 10 ng/kg d,l cyclazocine disrupted re-
sponding as compared to cyclazocine vehicle sessions (Adam-
Carriere et al., 1978). 
Cyclazocine produces increases in response rate in pi-
geons trained on an FR30 Fl5 schedule of reinforcement (Mc-
Millan and Harris, 1972). High doses of cyclazocine caused 
a decrease in resp:>nserates. L-cyclazocine was found to be 
30 times more potent in this effect than d-cyclazocine. 
A syndrome of animal behavior consisting of lateral 
head movements, pivoting on the hind paws and walking back-
wards has been shown to emerge in a dose dependent fashion 
in the rat following administration of cyclazocine, levallor-
phan, pentazocine, nalorphine, phencyclidine, atropine, 
mescaline and psilocybin but not following morphine, profodol 
or saline (Schneider, 1968). It is believed that observation 
of this syndrome is predictive of the psychotomimetic ef-
fects produced by these drugs. This bizarre behavior pro-
duced by cyclazocine and levallorphan is antagonized by apo-
morphine, piribedel, amphetamine, benztropine and 1-dopa 
(Buckett and Shaw, 1975), indicating that dopaminergic sys-
tems are involved in the production of these behaviors and 
suggesting dopaminergic involvement in the psychotomimetic 
effects produced by these drugs. 
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E. Discriminative Stimulus Properties of Cyclazocine 
The narcotic agonist-antagonist cyclazocine produces 
a discriminative stimulus which controls operant responding 
in the rat (Hirschhorn, 1977; Rosecrans et al., 1978; Teal 
and Holtzman, 1980) and the squirrel monkey (Schaeffer and 
Holtzman, 1978). The discriminative stimulus properties of 
cyclazocine are attenuated by the pure narcotic antagonist 
naloxone (Hirschhorn, 1977; Rosecrans et al., 1978; Schaeffer 
and Holtzman, 1978) but the dose of naloxone requir~d to 
block the discriminative stimulus produced by cyclazocine is 
from four to eighty times greater than the dose of naloxone 
required to block the discriminative stimulus produced by 
morphine (Gianutsos and Lal, 1975; Hirschhorn, 1977; Rose-
crans et al., 1978; Schaeffer and Holtzman, 1978). 
The discriminative stimulus produced by cyclazocine 
generalizes to the narcotic agonist-antagonists butorphanol, 
oxilorphan, levallorphan (Schaeffer and l~ltzman, 1978), the 
sigma agonist SKF 10,047 (Teal and Holtzman, 1979), ketocy-
clazocine (Schaeffer and Holtzman, 1978; Teal and Holtzman, 
1979) and nalorphine (Rosecrans et al., 1978). Naloxone re-
versed cyclazocine generalization to butorphanol and keto-
cyclazocine but was not effective in antagonizing generaliza-
tion to oxilorphan or levallorphan (Schaeffer and Holtzman, 
1978). Cyclazocine did not generalize to morphine, pentazo-
cine, naloxone, nalbuphine or nalmexone (Hirschhorn, 1977; 
Schaeffer and Holtzman, 1978; Teal and Holtzman, 1979). 
17 
Cyclazocine produced drug appropriate responding in rats 
trained to discriminate fentanyl from saline (Colpaert et 
al., 1976) or morphine from saline (Hirschhorn and Rosecrans, 
1976; Shannon and Holtzman, 1976, 1977), although these gen-
eralizations were not complete. 
Based on reports that the subjectively experienced ef-
fects produced by cyclazocine in humans are psychotomimetic 
in nature (Martin et al., 1965; Haertzen, 1970), several in-
vestigations have explored the possibility that the discrim-
inative stimulus produced by cyclazocine in laboratory ani-
mals may be based upon similar central mechanisms. Results 
indicate that cyclazocine did not generalize to the non-
opioid psychoactive drugs scopolamine, a-amphetamine, mesca-
line, pentobarbital or LSD (Schaefer and Holtzman, 1978; 
Hirschhorn, 1977), but did generalize to ketamine and phen-
cyclidine (Teal and Holtzman, 1979). This latter effect was 
not antagonized by naloxone. 
In rats trained to discriminate LSD from saline, cycla-
zocine was found to substitute for LSD, although the gener-
alization was only partial (Hirschhorn and Rosecrans, 1976). 
Pentazocine, a narcotic agonist-antagonist which pro-
duces central effects similar to cyclazocine (Martins et al., 
1976), produces a discriminative stimulus in the rat (Kuhn 
et al., 1976). The discriminative stimulus strength of pen-
tazocine is subject to attenuation by the neuroleptic, halo-
peridol (Appel et al., 1978). 
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F. Discriminative Stimulus Produced by Narcotic Drugs 
The narcotic analgesics, of which morphine is the 
prototype, are a group of centrally acting agents whose prin-
cipal effects include reduction of pain sensitivity, respir-
atory depression and the production of a euphoric state in 
human subjects (Jaffe and Martin, 1975). Despite its effi-
cacy in reducing the perception of pain, the usefulness of 
morphine and other narcotics has been reduced by the fact 
that tolerance develops to many of its central effects and 
that physical dependence and addictive behavior are observed 
following repeated administration. 
Several clinical studies have indicated that the self 
administration of narcotics is related to the subjective ef-
fects produced by these drugs (Eddy et al., 1970; Fraser 
et al., 1961. 
Recently, the discriminative stimulus properties of nar-
cotic drugs were shown to be closely related to their cen-
trally induced subjective effects (for discussion see Lal 
et al., 1977; Colpaert, 1977). In an effort to determine 
the nature of these subjective effects, much attention has 
been recently directed toward mechanisms underlying the dis-
criminative stimulus produced by narcotic drugs. 
The discriminative stimulus strength of morphine 
(Shannon and Holtzman, 1976; Miksic and Lal, 1977) and fen-
tanyl (Colpaert et al., 1975) have been shown to be dose re-
lated in nature in the rat. Similarly, the morphine discrim-
inative stimulus also generalizes to other narcotic drugs in 
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a dose dependent manner (Shannon and Holtzman, 1977; Miksic 
et al., 1978) but does not generalize to non-narcotic psy-
- -
choactive drugs (Gianutsos and Lal, 1976; Miksic et al., 
The narcotic antagonist naloxone (Gianutsos and Lal, 
1976) and naltrexone (Shannon and Holtzman, 1977) produce 
antagonism of the discriminative stimulus properties of mor-
phine, while not producing drug appropriate responding when 
injected alone. 
The discriminative stimulus of morphine has been shown 
to be based upon central rather than peripheral mechanisms 
of this drug. The principal peripheral effect of morphine 
is decreased intestinal motility, thus leading to an anti-
diarrheal use of morphine (Jaffe and Martin, 1975). Loper-
amide, a potent antidiarrheal agent (Stokkrehx et al., 1973) 
which is devoid of analgesic and other mrophine-like central 
effects (niemegeers et al., 1974), failed to produce drug 
appropriate responding when administered to animals trained 
to discriminate morphine from saline (Gianutsos and Lal, 
1975). 
It has also been demonstrated that the discriminative 
stimulus properties of morphine are not based upon the anal-
gesic effects of morphine. Animals trained to discriminate 
morphine and then subjected to increasing doses of morphine, 
are still able to clearly discriminate the narcotic effect 
although they have become tolerant to the analgesic proper-
ties of morphine (Miksic and Lal, 1977). 
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The discriminative stimulus produced by fentanyl was an-
tagonized by pretreatment with the neuroleptic pimozide, 
while alpha methy l paratyrosine, azaperone, chlorpromazine 
or pipamperone were not effective in blocking fentanyl dis-
crimination (Colpaert~! al., 1977). 
The nature of generalization of the morphine discrimina-
tive stimulus to the narcotic agonist-antagonists has .recent-
ly been shown to be determined by the training dose of mor-
phine (Shannon and Holtzman, 1979). A low training dose 
(l . 25 mg/kg) of morphine generalized completely to the narcot-
ic antagonist nalbuphine and d-amphetamine and partially 
generalized to cyclazocine while a higher training dose (5.6 
mg/kg) only partially generalized to nalbuphihe and did not 
generalize to a-amphetamine or cyclazocine. 
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III. METHODS AND lffiTERIALS 
A. Animals 
Fourteen male hooded rats of the Long-Evans strain, 
random bred at the Charles River Breeding Laboratories, 
Wilmington, Massachusetts and weighing between 300 and 350 
grams were used in the discrimination experiments. Animals 
were singly housed in a room thermostatically controlled at 
21 + 1°C with house lights turned off between 8 P.M. and 8 
A.M. Water was continuously available but food was limited 
to approximately 20 grams per day made available 2 to 4 hours 
following each daily session. Animals' weights were main-
tained at approximately 300 grams using this feeding sched-
ule. 
B. Drugs 
Aceperone, benperidol, halopomide, haloperidol, oxi-
peromide and pipam perone were obtained through Janssen Phar-
maceutica, Beerce, Belgium. Cyclazocine, ethylketocyclazo-
cine and pentazocine were made available through the courtesy 
of Sterling Wintrhop Research Laboratories, Rennsalear, New 
York. Dextro-amphetamine sulfate and chlorpromazine was ob-
tained from Smith, Kline and French Inc., Philadelphia, 
Pennsylvania. Endo Laboratories of Garden City, New York 
generously provided naloxone hydrochloride. D-butaclamol, 
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1-butaclamol and dexclamol were supplied by Ayerst Laborator-
ies of Montreal, Canada . Nalorphine hydrochloride and ami-
triptyline were obtained from the Merck Co. Inc. The Upjohn 
Co. of Kalamazoo, Michigan generously provided the clozapine, 
U 49,274A (Phenol, m-(8-(butylmethylamino)-l,4-dioxaspiro(4.5)-
dec-8-yl)-hydrochloride) and U-50,488E (Acetamide,2,-(3,4-
dichlorophenyl)-N-methyl-N-(2-(l-pyrrolidinyl)cyclohexyl)-, 
trans-, monohydrochloride, hemihydrate). 
C. Equipment 
Experiments were conducted in standard sound atten-
uated lever boxes obtained from Lehigh Valley Electronics, 
Fogelsville, Pennsylvania . Chambers were equipped with two 
levers attached to one wall, placed equidistant on either 
side of the food cup. 
Boxes were electronically programmed for responses on 
only one of the levers to be reinforced while responses on 
the opposite lever were not reinf~rced. Automatic counters 
were used to record the number of reinforcements delivered, 
the number of incorrect responses made before delivery of 
the first reinforcement and the total number of incorrect 
responses made during a training session. 
Forty-five milligram food pellets obtained from the 
P.J. Noyes Company of Lancaster, New Hampshire were used 
for reinforcement. 
D. Trainin g Procedure 
Discrimination training sessions were conducted 
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on a daily basis. Animals trained for cyclazocine discrim-
ination were injected with either cyclazocine (1.25 mg/kg) 
or saline (1 ml/kg) fifteen minutes prior to being placed in 
the operant chambers. Animals trained for morphine discrim-
ination were injected with either morphine (10 mg/kg) or 
saline (1 ml/kg) 15 minutes prior to being placed in the 
operant chamber. All training sessions were ten minutes 
long. Injection of drug or saline were alternated according 
to an irregular sequence of injections. 
Initial training sessions were conducted on a fixed ra-
tio of one response for a reinforcement with the reinforced 
lever alternated randomly. No injections were given during 
these initial trials. When response rates on the FRl were 
stabilized, the fixed ratio was gradually increased over the 
course of several training sessions until an FRlO was 
reached. At this point drug and saline injections were be-
gun. Each animal was assigned one lever as the drug lever 
and the alternate lever as the saline lever. Half of the 
animals were reinforced on the left lever following drug ad-
ministration and the right lever following saline injection. 
Lever assignments were opposite to this in the remainder of 
the animals. These lever assignments did not change for the 
remainder of the experiment. 
Training sessions consisted of placing the animals in 
the lever boxes 15 minutes after drug or saline administra-
tion. Once placed in the chambers, the animals were allowed 
to respond. Responseson the reinforced lever were recorded 
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as number of reinforcements delivered. The actual number of 
responses made on the reinforced lever was 10 times the num~ 
ber of reinforcements. A separate recording was made of the 
number of responses made on the non-reinforced lever before 
the delivery of the first reinforcement. When the first re-
inforcement had been delivered, this recorder was automati-
cally deactivated. 
Responses made on the non-reinforced lever throughout 
the training sessions were recorded separately. This in-
eluded responses made on the non-reinforced lever before and 
after the delivery of the first reinforcement. 
When animals made not more than four incorrect responses 
before the first reinforcement on ten consecutive training 
days, they were considered to meet the discrimination cri-
terion and were used for generalization testing. 
E. Testing Procedure 
Testing was conducted once per week per animal in 
the animals which maintained proper discriminative respond-
ing. On generalization test days, animals were injected 
with the test drug, fifteen minutes after which they were 
placed in the operant chambers and allowed to complete ten 
responses on one of the levers. Responses on the opposite 
lever were also recorded. When ten responses had been re-
corded on either of the levers, the animal was removed from 
the operant chamber and returned to the home cage. The test 
was recorded as a drug selection or a saline selection based 
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upon which lever ten responses were completed first. 
Drugs being tested for blockade or potentiation of the 
cyclazocine or morphine discriminative stimuli were injected 
at a predetermined interval before injection of cyclazocine, 
morphine or one of the agents to which the training drugs 
generalized. Fifteen minutes following this second injec-
tion, a test, as described above , was conducted. 
Discrimination training was conducted between tests with 
eaah animal receiving drug and saline at least twice between 
tests. All tests were conducted on a day following a saline 
training session. Training sessions were conducted at least 
six days per week. 
F. Analgesia Testing 
Male albino mice of the CD-1 strain obtained from 
the Charles River Breeding Laboratories were employed in the 
analgesia experiments. Mice were used in this portion of 
the experiment due to inconsistency of cyclazocine analgesia 
when demonstrated in the rat. The tail flick apparatus was 
EMDIE model TF-6. 
Animals were hand-held in order that their tails could 
be placed on the notched block so as to occlude the aperture 
from the photocell. Turning on the 100 watt heat lamp caused 
simultaneous activation of a timer. The lamp was placed 
13 cm. above the platform so that heat was directed upon the 
animal's tail. When the animal flicked its tail, the photo-
cell was exposed to the light and the timer was automatical-
ly stopped. The intensity of the larr.p was adjusted so that 
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control latencies ranged from two to four seconds. Latencies 
were recorded to 0.1 sec. Animals with latencies outside of 
this range were always discarded from the experiment. 
In measuring cyclazocine analgesia, control latencies 
were recorded for each animal. Cyclazocine was then adminis-
tered at the predetermined doses. Tail flick latency was 
recorded five minutes and 35 minutes following cyclazocine 
administration. When investigating possible drug induced al-
teration of cyclazocine analgesia, the drug being employed 
in combination with cyclazocine was administered after con-
trol latencies were recorded. With several animals from each 
group, a second recording was done before cyclazocine admin-
istration to insure that pretreatment agents did not have 
analgesic properties themselves. 
Oxiperomide, haloperidol, pipamperone, halopomide 
(R-34-301), 1-butaclamol and aceperone were administered 60 
minutes prior to cyclazocine. Clozapine and dexclamol were 
injected 30 minutes before cyclazocine while naloxone was 
injected 10 minutes before cyclazocine. 
Analgesic latencies were defined as those which exceeded 
the group control mean by more than three standard devia-
tions. All data is recorded as percent animals tested with 
analgesic latencies. 
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IV. RESULTS 
A. Training 
Animals trained to discriminate cyclazocine (1.25 
mg/kg) from saline met testing criteria in 41.50 ~ 1.66 
training sessions (n=l4) (Table 1) . Several animals were 
sedated by the training dose of cyclazocine and were unable 
to respond during several of the initial drug training ses-
sions. Tolerance to this effect was observed in all cases 
within three training sessions . 
. In agreement with previous results (Miksic, Shearman 
and Lal, 1978; Miksic and Lal, 1977; Gianutsos and Lal, 1975), 
the morphine saline trained animals met testing criteria in 
fewer than 40 training sessions. 
B. Generalization-Cyclazocine Discriminative Stimulus 
In animals trained to discriminate cyclazocine from 
saline, 100 % of animals tested responded on the drug lever 
following administration of the cyclazocine training dose of 
1.25 mg/kg. The average response rate during cyclazocine 
training sessions was 85.3 + 7.4 responses per minute (n=l4) 
(Table 2). Following saline injection (1 ml/kg), 100% of 
the animals tested responded on the saline lever. The re-
sponse rate during saline training sessions was 93.6 + 7.3 
responses per minute (n=l4) (Table 2) . 
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TABLE 1. NUMBER OF TRIALS REQUIRED TO MEET TESTING CRITERIONl 
IN ANIMALS TRAINED TO DISCRIMINATE CYCLAZociNE 
(1.25 mg/kg) 2 FROM SALINE. 
Animal No. # Trials 
1 45 
2 50 
3 42 
4 41 
5 39 
6 52 
7 46 
8 41 
9 47 
10 30 
11 35 
12 36 
13 42 
14 35 
Mean + S.E. 41.5 + 1.6 
1. Testing criterion was to not emit more than four re-
sponses on the incorrect lever before the first rein-
forcement on ten consecutive trials. 
2. Administered 15 minutes before training session. 
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TABLE 2. RE SPONSE RATES FOR ANI MALS TRAINED TO DISCRIMINATE 
CYCLAZOCINE FROM SALINE 
l 
Res ponses per 10 Minute Session (Mean + S . E . ) 
Animal No. Cyclazocine 2 Saline 
l 443 + 41 556 + 45 
-
2 1401 + 33 1309 + 51 
-
-
3 735 + 38 873 + 39 
- -
4 850 + 52 924 + 75 
- -
5 774 + 39 933 + 44 
6 684 
-+ 26 718 + 40 
- -
7 1047 + 54 1059 + 47 
-
8 740 + 90 1453 + 53 
-
-
9 6 34 + 59 977 + 62 
- -
10 1341 + 56 1297 + 29 
-
11 731 + 65 890 + 90 
- -
12 817 + 29 897 + 49 
- -
13 614 + 38 , 590 + 40 
- -
14 1129 + 67 625 + 53 
- -
Mean + S.E. 853 + 74 936 + 73 
- -
1. Based on 10 consecutive determinations commencing on 
day 150 of the experiment. 
2. 1.25 mg/kg, administered 15 min. before measurement. 
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Injection of the cyclazocine vehicle, 0.3% tartaric acid 
resulted in 100 % saline lever selection with response rate 
being similar to those observed following saline. 
When the dose of cyclazocine was decreased on a log dose 
basis, a dose related decrease in percent animals selecting 
the drug lever was recorded (r=0.91) (Table 3). 
Following administration of the partial agonist antago-
nist ethylketocyclazocine, rats trained to discriminate cy-
clazocine from saline selected the drug lever in a dose 
dependent fashion (r=0.91) (Table 3). One hundred percent 
of the animals tested selected the drug lever following 
ethylketocyclazocine 0.32 mg/kg. 
The narcotic agonist-antagonist pentazocine produced 
dose related increases in percent animals selecting the drug 
lever with 100 % selecting the drug lever following a dose of 
20 m/gkg. Increasing the pentazocine dose to 40 mg/kg re-
sulted in a decrease in the ratio of animals selecting the 
drug lever with 70% selecting the drug lever following this 
dose (Table 3). 
U-49,274A and U-50,488E, experimental narcotic agonist-
antagonists produced by the Upjohn Company, each produced 
drug lever selection. The highest dose of U-49,274A tested 
(40 mg/kg) resulted in 40 % drug lever selection with 60 % of 
the animals tested unable to respond. No higher doses were 
tested. 
The highest percent animals selecting the drug lever 
following U-50,488E was 50 % following 10 mg/kg with percent 
TABLE 3. 
Drug Dose N 
CYCLAZOCINE 0.005 9 
0 . 02 16 
0.08 11 
0 . 32 8 
0.64 15 
1. 25 14 
2 . 50 7 
ETHYLKETOCYCLAZOCINE 0 . 08 6 
0.16 4 
0 . 32 4 
NALORPHINE 0.64 4 
2.50 7 
1 0 . 00 8 
GENERALIZATION OF THE DISCRIMINATIVE STIMULUS 
PRODUCED BY CYCLAZOCINE (1. 25 mg/kg) TO 
NARCOTIC DRUGSl 
% Selecting 
Cyclazocine Lever 
0 
25 
27 
32 
87* 
100* 
100* 
17 
25 
100* 
25 
43 
100* 
Responses on Unselected Lever 
Before First Reinforcement 
(Mean + S . E . ) 
Following 
Drug Selection 
No drug selection 
0.38+0 . 38 (16) 
-
0 
1. 67+0 . 88 ( 5) 
-
0 . 23+0 . 23 (13) 
0 
0 
0 
0 
2 . 50+1. 66 (4) 
0 
2.67+2 . 19 ( 3) 
1.13+0. 74 (8) 
Following 
Saline Selection 
1.58+0.80 ( 12) 
-
0 
1.60+1.60 ( 5) 
0 
No saline selection 
No saline selection 
2 .40+1 . 36 ( 5) 
-
0 
No saline selection 
2 . 33+2 . 33 ( 3) 
-
1.50+0 . 63 (4) 
-
No saline solution 
w 
t-' 
TABLE 3 (continued) 
Responses on Unselected Lever 
Before First REinforcement 
(Me an + S . E . ) 
% Selecting Following Following 
Drug Dose N Cyclazocine Lever Drug Selection Saline Selection 
PENTAZOCINE 2.50 7 14 1.00+0 (1) 0 
-
10.00 5 80 3 . 25+1.18 (4) 9.0+0 (1) 
- -
20.00 5 100 1. 20+1. 20 ( 5) No saline selection 
-
40.00 10 70 1.43+0.69 ( 7) 2.33+1.86 ( 3) 
- -
U-49, 274A 20.00 8 25 3.00+2.45 ( 2) 3.17+1.62 ( 6) 
- -
40.00 5 60 0 5.67+1.86 (3) 
-
u-50, 488E 2.50 5 20 5.00+0 (1) 0.50+0.29 ( 4) 
- -
10.00 8 50 0 2 .00+1. 35 (4) 
-
20.00 4 25 8.00+0 ( 1) 0 
-
MORPHINE 2.50 6 17 0 1.60+1.36 ( 5) 
-
5.00 8 50 1.75+0.85 (4) 0 
-
10. 00 6 100 3.67+1.65 (6) No saline selection 
-
NALOXONE 0.16 7 0 No drug selection 0 
10.00 9 0 No drug selection 0.40+0.24 (5) 
-
40.00 5 0 No drug selection 0 
lAll drugs and doses administered 15minutes prior to testing. 
*Statistically significant difference (p~0.05) by Fisher Exact Probability in comparison with 100% w 
saline lever selection (n=l4) . l\J 
selecting the drug lever decreasing to 25% following a dose 
of 20 mg/kg. 
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The discriminative stimulus produced by cyclazocine 
completely generalized to the pure narcotic agonist morphine 
(Table 3). Dose related increases in percent selection of 
drug lever were observed with 100% drug lever selection fol-
lowing a dose of 10 mg/kg (r=0.99). 
The pure narcotic antagonist, naloxone, produced saline 
lever selection in all animals tested and at all doses tested 
from 0.64 mg/kg to 40.0 mg/kg. 
In order to investigate the possible biogenic amine ba-
sis of the cyclazocine discriminative stimulus, selected 
agents were tested for generalization to the cyclazocine dis-
criminative stimulus. 
The direct and indirect dopamine receptor stimulants 
apomorphine and a-amphetamine were tested for generalization. 
All doses of apomorphine tested produced saline lever selec-
tion (Table 4). In the case of a-amphetamine, a dose of 0.64 
mg/kg generalized to saline. A dose of 1.25 mg/kg resulted 
in two of the five animals tested selecting the drug lever. 
Dopaminergic receptor blockers also produced saline 
lever selection. The agents used in these tests included 
bemperidol (0.32 mg/kg), d-butaclamol (0.16 mg/kg), 1-buta-
clamol (0.16 mg/kg), clozapine (5.0 mg/kg), dexclamol (0.16 
(mg/kg), haloperidol (0.32 mg/kg) and oxiperomide (0.16 mg/kg) 
(Table 4). 
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TABLE 4. GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PRODUCED BY 
CYCLAZOCINE (l.25 mg/kg) TO NON-NARCOTIC PSYCHOACTIVE DRUGS 
Responses on Incorrect Lever 
(Mean + S .E.) 
Drug 
Drug Dose (mg/kg) N Lever Q_rug Selection Saline Selection 
-- ---
APOMORPHINE 0.64 4 0 2. 50+1. 50 (2) 
1.25 l 0 0 
d-AMPHETAMINE 0.16 3 0 0 
0.64 7 0 0 
1.25 5 40 0.50+0.50 ( 2) 1.0+0 (2) 
HALOPERIOOL 0 .. 32 4 0 0 
d-BUTACLAMOL 0.16 5 0 0 
1-BUTACLAMOL 0.16 6 0 0 
BENPERIOOL 0. 32 5 0 0 
CLO ZAP I NE 5.00 9 0 0 
OXIPEROMIDE 0.16 7 0 0 
DEXCLAMOL 0.16 5 0 0 
HALOPOMIDE 2.50 2 0 0 
10 .00 6 0 0 
CLONIDINE 0.16 4 0 0 
DESIPRAMINE 10.00 9 0 0 
AMITRIPTYLINE 30.00 3 0 0 
ACEPERONE 2 .50 5 20 0 0 
BUTORPHANOL 0.16 4 0 0. 75+0. 75 (4) 
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Halopomide (R34-301), a compound which reportedly blocks 
peripheral dopaminergic receptors, ·when tested for general-
ization at doses of 2.50 and 10.0 mg/kg resulted in 100% sa-
line lever selection. 
Clonidine (0.16 mg/kg), an alpha1 adrenergic agonist, pro-
duced saline lever selection (Table 4). 
The tricyclic antidepressants amitriptyline and desipra-
mine both produced saline lever selection in all animals 
tested (Table 4). 
Aceperone, an alpha adrenergic blocker, administered at 
a dose of 2.50 mg/kg produced 20% drug lever selection (n=5) 
(Table 4). Butorphanol reportedly having narcotic agonist-
antagonist properties produced 100% saline lever selection 
(Table 4). 
C. Naloxone Blockade of Cyclazocine Discriminative Stimulus 
In agreement with previous reports (Hirschhorn, 1977; 
Rosecrans et al., 1978; Schaeffer and Holtzman, 1978; Teal 
and Holtzman, 1980), naloxone produced a dose dependent block-
ade of the cyclazocine discriminative stimulus (Table 5). 
Naloxone administered in doses of 2.5 or 10.00 mg/kg fifteen 
minutes prior to the cyclazocine training dose resulted in 
diminished percent drug lever selection. Complete blockade 
of the cyclazocine discriminative stimulus was observed fol-
lowing naloxone 40 mg/kg i.e., 100 % of the animals tested se-
lected the saline lever. 
Naloxone 
Dose (mg/kg) 
0 
0.64 
2.50 
10.00 
40.00 
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TABLE 5. ANTAGONISM OF DISCRIMINATIVE STIMULUS PRODUCED 
BY CYCLAZOCINE (l. 2S mg/kg) BY NALOXONEl 
N 
14 
6 
5 
7 
5 
% Selecting 
Cyclazocine 
Lever 
100* 
100* 
60* 
14 
0 
Responses on Unselected Lever 
Before First Reinforcement 
(Mean + S . E . ) 
Following Drug 
Lever Selection 
0 
0 
0 . 33+0.33 (3) 
0 
No drug selection 
Following Saline 
Lever Selection 
No saline selection 
No saline selection 
0 
1. 67+0 .80 ( 6) 
0 
1. Naloxone administered 15 minutes prior to cyclazocine (1. 25 mg/kg) 
2. Statistically significant difference (pL 0.05) by Fisher Exact 
Probability in comparison with 100% saline lever selection (n=l4). 
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Naloxone also antagonized generalization of the cyclazo-
cine discriminative stimulus to morphine (10 mg/kg) (Table 6). 
Complete blockade of this generalization was achieved follow-
ing naloxone 1.25 mg/kg. 
Generalization of the cyclazocine discriminative stimu-
lus to nalorphine (10 mg/kg) was not completely blocked by 
naloxone at any dose of naloxone tested (Table 7). Although 
naloxone at a dose of 0.64 mg/kg reduced percent drug lever 
selection from 100% to 57%, further increases in the naloxone 
dose, up to 40 mg/kg, resulted in approximately 25% drug le-
ver selection. 
D. The Effects of Neuroleptics Upon the Cyclazocine Discrim-
inative Stimulus 
In order to investigate a possible dopaminergic com-
ponent in the cyclazocine discriminative stimulus, several 
neuroleptics were employed as pretreatments to cyclazocine 
before generalization testing. Initial portions of this ser-
ies of experiments were conducted at the training dose of 
cyclazocine, 1.25 mg/kg. The dosages of neuroleptics which 
were used in these experiments were decided upon in light of 
previous results in animal experimentation using these same 
drugs. 
The neuroleptic, d-butaclamol, when administered at a 
dose of 0.16 mg/kg 60 minutes prior to cyclazocine, produced 
a statistically significant attenuation of the cyclazocine 
discriminative stimulus (Table 8. 
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TABLE 6. ANTAGONISM OF CYCLAZOCINE DISCRIMINATIVE STIMULUS 
GENERALIZATION TO MORPHINE (10 mg/kg) BY NALOXONE 
% Selecting 
Naloxone Cyclazocine 
Dose (mg/kg) N Lever 
0 6 100* 
0.08 5 80* 
0.32 6 so 
1.25 4 0 
Responses on Unselected Lever 
Before First Reinforcement 
(Mean + S.E.) 
Following Drug 
Lever Selection 
0 
4 . 25+1.93 (4) 
0 
Following Saline 
Lever Selection 
No saline selection 
0 
0 
No drug selection No saline selection 
1. Naloxone administered 15 minutes prior to morphine (10 mg/kg). 
* Statistically significant difference (pL 0 . 05) by Fisher Exact 
Probability in comparison with 100% saline lever selection (n=l4). 
TABLE 7. ANTAGONISM OFCYCLAZOCINE DISCRIMINATING STIMULUS 
GENERALIZATION TONALORPHINE (10 mg/kg) BY 
NALOXONEl 
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Responses on Unselected Lever 
Before First Reinforcement 
(Mean + S.E.) 
% Selecting 
Naloxone Cyclazocine Following Drug Following Saline 
Dose (mg/kg) N Lever Lever Sele·ction Lever Selection 
0 4 100% 1.13+0. 74 ( 8) No saline selection 
0.64 7 57* 0.25+0.25 (4) 0 
2.50 8 25 .3.50+3.50 (2) 1. 33+1. 33 (8) 
10 .00 8 38 2. 00+1. 53 ( 3) 0 
20.00 9 11 0 0 
40.00 8 25 3.00+3.00 (2) 0 
1. Naloxone administered 15 minutes prior to nalorphine. 
* Statistically significant difference (pL0.05) by Fisher Exact 
Probability in comparison with 100% saline lever selection (n=l4). 
TABLE 8. THE EFFECTS OF NEUROLEPTIC PRETREATMENT UPON DISCRIMINATIVE STIMULUS PRODUCED BY CYCLAZOCINE 
Responses on Unselected Lever 
Before First Reinforcement 
(Mean + S . E: ) 
Dose % Selecting Following Drug Following Saline 
Dose (mg/kg} Drug (mg/kg} N Cyclazocine Lever Lever Selection Lever Selection 
1. 25 14 100* 0 No saline selection 
d-BUTACLAMOL 0 .16 6 33 0 0 
1-BUTACLAMOL 0.16 6 100* 0 No saline selection 
HALOPERIDOL 0. 32 7 57* 3.00+0 (1) 4.00+0 (1) 
-
OXIPEROMIDE 0 .16 7 100* 7.00+0 ( 1) No saline selection 
-
OXIPEROMIDE 0.64 4 100* 0 No saline selection 
1. Neuroleptics administered one hour prior to cyclazocine (.25 mg/kg). 
* Statistically significant difference (pL0. 05 ) by Fisher Exact Probability in comparison with 
100 % saline lever selection(n=l4). 
8 
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L-butaclamol, an enantiomer devoid of neuroleptic activ-
ity, was ineffective in altering the . discriminative stimulus 
strength of cyclazocine (Table 8) . 
Haloperidol (0.32 mg/kg), a member of the butyrophenone 
series of neuroleptics, produced a blockade of the cyclazo-
cine discriminative stimulus which was not significantly dif-
ferent from saline pretreatment (Table 8). 
Oxiperomide, a dopaminergic antagonist specifically ac-
tive in the gut and at the chemoreceptor trigger zone, did 
not produce a blockade of the cyclazocine discriminative 
stimulus at either of the two doses tested (0.16 mg/kg) and 
0. 64 mg/kg) (Table 8) . 
In view of the fact that the discriminative stimulus 
strength of cyclazocine at a dose of 1.25 mg/kg might repre-
sent a plateau effect at the higher ranges afthe dose-re-
sponse curve, and that the possible blocking properties of 
neuroleptics tested might be masked by such an effect, addi-
tional experiments dealing with cyclazocine discriminative 
stimulus blockade by neuroleptics were conducted with cycla-
zocine 0.64 mg/kg. 
In subsequent experimentation, haloperidol (0.32 mg/kg) 
produced a blockade of the cyclazocine discriminative stim-
ulus which was statistically significant (Table 9). In this 
test, the percent animals selecting the drug lever was de-
creased from 87 % (n=l5) with no pretreatment to 18% (n=ll) 
with haloperidol pretreatment. 
TABLE 9. 
Cyclazocine 
Dose (mg/kg) Drug 
1 
THE EFFECTS OF NEUROLEPTIC PRETREATMENT UPON THE DISCRIMINATIVE STIMULUS 
PRODUCED BY CYCLAZOCINE 
Dose 
(mg/kg) N 
-
% Selecting 
~clazocine Lever 
Responses on Unselected Lever 
Befor e First Reimforcement 
(Mean+ S.E.) 
Following Drug Following Saline 
Lever Selection Lever Selection 
0.64 15 87* 3.00 + 0 ( 1) No saline selection 
BENPERIOOL 
CLOZAPINE2 
CLOZAPINE2 
DEXCLAMOL 
HALOPERIOOL 
HALOPERIDOL 
0.32 
5.00 
10. 00 
0.16 
0.08 
0.32 
5 
9 
6 
5 
9 
11 
-
20 0 
56* 0 
67* 0 
60 4.00 + 0 
100* 0 
18 0 
1. Neuroleptics administered one hour prior to cyclazocine (0.64 mg/kg) 
2. Clozapine administered 30 minutes prior to cyclazocine. 
0 
8.00 + 0 ( 3) 
-
0 
(1) 4.00 + 0 ( 1) 
-
0 
0 
* Statistically significant difference (pL0.05) by Fisher Exact Probability in comparison with 
100% saline lever selection (n=l4) . 
.t> 
;0 
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A smaller dose of haloperidol was found to be ineffec-
tive in blocking the discriminative - stimulus properties of 
cyclazocine. 
A similar attenuation of the cyclazocine discriminative 
stimulus was observed following pretreatment with benperidol 
(0.32 mg/kg) 60 minutes prior to cyclazocine (0.64 mg/kg) 
(Table 9). 
Clozapine, a weak neuroleptic which produces few extra-
pyramidal side effects, was found to produce some blockade of 
the cyclazocine discriminative stimulus, although this effect 
of clozapine was not found to be statistically significant 
(Table 9). 
Similarly, dexclamol, a soluble form of the previously 
mentioned butaclamol, was found to have stimulus blocking 
effects which were not within a statistically significant 
range (Table 9). 
E. The Effects of D-Amphetamine Upon the Cyclazocine Dis-
criminative Stimulus 
D-amphetamine (0.64 mg/kg) pretreatment fifteen 
minutes prior to cyclazocine administration caused no detect-
able change in the discriminative stimulus properties of cy-
clazocine (Table 10). 
F. Generalization - Morphine Discriminative Stimulus 
Animals trained to discriminate morphine (10 mg/kg) 
from saline (1 ml/kg) selected the drug lever 100% of the 
trials following this training dose. The percent animals 
d-Ampetamine 
Dose (mg/kg) 
0.64 
0.64 
0.64 
0 . 64 
TABLE 10. THE EFFECTS OF d-AMPHETAMINE PRETREATMENTl UPON THE 
DISCRIMINATIVE STIMULUS PRODUCED BY CYCLAZOCINE 
Cyclazocine % Selecting 
Dose (mg/kg) N Drug Lever 
0 7 0 
0.02 7 14 
0.08 7 57 
0.32 7 71 
Responses on Unselected 
Lever (Mean+ S.E.) 
Following Drug 
Lever Selection 
1. 0 + 0 ( 1) 
2.50 + 1.66 (4) 
0 
Following Saline 
Lever Selection 
0 
0 
3.67 + 2.67 (3) 
0 
1. Administered 15 minutes prior to cyclazocine. 
.s::. 
~ 
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selecting the drug lever decreased with decreases in the dose 
of morphine administered (r=0.89) (Table 11). 
The partial agonist-antagonist, cyclazocine, produced 
drug lever selection in animals trained to discriminate mor-
phine from saline. This generalization was not complete in 
that at no dose tested did 100 % of the animals tested select 
the drug lever (r=Q.90) (Table 12). 
Ethylketocyclazocine, also a partial agonist-antagonist, 
produced drug lever selection in animals trained to discrimi-
nate morphine from saline (Table 12) . Increases in percent 
animals selecting drug lever was observed when the dose of 
ethylketocyclazocine was increased fron 0.08 mg/kg to 0.32 
mg/kg. Further increases in dose to 0.64 mg/kg and 1.25 
mg/kg produced a percent drug lever selection decrease. 
The pure narcotic antagonist, naloxone, produced exclu-
sive saline lever selection at all doses tested (Table 12). 
G. Naloxone Blockade of .Morphine Discriminative Stimulus 
Naloxone produced a dose dependent blockade of the 
morphine discriminative stimulus when administered 15 min-
utes prior to morphine injection (r=0.99) (Table 13). Com-
plete blockade was recorded following naloxone 0.32 mg/kg. 
When nalo xone was administered 15 minutes prior to cy-
clazocine (1.25 mg/kg) in rats trained to discriminate mor-
phine from saline, there was a diminished percent animals 
selecting the drug lever as compared to saline injection or 
TABLE 11. RESPONSE RATES FOR ANIMALS · TRAINED TO DISCRIMINATE 
MORPHINE FROM SALINE 
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Responses per 10 Minute Session (Mean + S .E.) 
Animal No. Morphine 2 Saline 
1 832 + 68 1240 + 59 
-
2 557 + 50 981 + 85 
-
3 600 + 64 989 + 50 
- -
4 748 + 45 1015 + 69 
-
5 736 + 77 1218 + 46 
6 181 + 35 795 + 72 
-
7 682 + 91 1097 + 62 
-
-
8 451 + 49 903 + 70 
-
9 200 + 16 446 + 60 
-
10 795 + 64 874 + 49 
- -
11 323 + 25 746 + 46 
-
12 590 + 16 972 + 42 
- -
Means + S. E. 558 + 65 940 + 62 
-
1. Bas e d upon 10 consecutive determinations commencing on day 150 of 
experiment. 
2. 10 mg/ kg, given 15 minutes before measurement. 
1 
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TABLE 12. GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PRODUCED BY 
MORPHINE (10 mg/kg) TO NARCOTIC DRUGs.l 
Responses on Unselected Lever 
Before Firs t Reinforcement 
% (Mean + S . E . ) 
Selecting 
Dose Morphine Following Drug Following Saline 
Drug (mg/kg) N Lever Lever Selection Lever Selection 
MORPHINE 0. 64 5 20 0 0 
1. 25 5 0 No drug selection 0 
2.50 17 47* 0 1.11+0. 75 (9) 
5.00 7 57* 1.50+1.19 (4) No saline selection 
10.00 12 100* 0 No saline selection 
CYCLAZOCINE 0.08 7 43 1.6741.67 ( 3) 1. 75+1. 03 ( 4) 
0.32 8 38 0.33+0.33 ( 3) 0 
1. 25 8 88* 0 0 
2.50 5 80* 0.25+0.25 ( 4) 0 
ETHYLKETO-
CYCLAZOCINE 0.08 5 0 No drug selection 0 
0.16 10 10 0 0 
0.32 7 71* 4.40+1.80 ( 5) 0 
0.64 4 50 3.00+1.73 ( 3) 0 
1.25 4 0 No drug selection 0 
NALOXONE 0.005 5 0 No drug selection 0 
0.08 5 0 No drug selection 0.40+0.40 ( 5) 
0.32 2 0 No drug selection 0 
1. All drugs and doses administered 15 minutes prior to testing. 
* Statistically significant difference (p LQ.05 ) by Fisher Exact Prob-
ability in comparison with 100% saline lever selection (n=l2) . 
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TABLE 13. ANTAGONISM OF DISCRIMINATIVE ' STIMULUS PRODUCED BY MORPHINE 
(10 mg/kg) BY NALOXONEl 
Responses on Unselected Lever 
Before First Reinforcement 
% (Mean + S.E. 
Selecting 
Naloxone Morphine 2 Following Drug Following Saline 
Dose (mg/kg) N Lever Lever Selection Lever Selection 
0 12 100* 6.891* 0 No saline selection 
0.08 4 100* 4.701* 0 No saline selection 
0.16 5 60 2.761 1.67+1.20 ( 3) 0 
0.32 6 0 No drug selection 0 
1. Naloxone administered 15 minutes prior to morphine (10 mg/kg). 
* Statistically significant diffe rence (pL.0.05) by Fisher Exact 
Probability in comparison to 100% saline lever selection (n=l2) . 
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no injection prior to cyclazocine (r= -0.98) (Table 14). Com-
plete blockade was observed following naloxone 1.25 mg/kg. 
Nonnarcotic psychoactive drugs which resulted in saline 
lever selection included d-butaclamol (0.16 mg/kg), 1-buta-
clamol (0.16 mg/kg), d-amphetamine (0.64 mg/kg), haloperidol 
(0.32 mg/kg), chlorpromazine (10 mg/kg) and clonidine (0.16 · 
mg/kg) (Table 15). 
H. The Effects of Neuroleptics Upon the Morphine Discrimina-
tive Stimulus 
The butyrophenone neuroleptic, haloperidol, when ad-
ministered at a dose of 0.32 mg/kg, 60 minutes prior to mor-
phine injection, produced a statistically significant decrease 
in the percent animals selecting drug lever follow1ng morphine 
at doses of 2.5 and 10 mg/kg when compared to saline pretreat-
ment before morphine at these doses (Table 16). 
Attenuation of the morphine discriminative stimulus was 
not observed following pretreatment with the neuroleptics 
d-butaclamol (0.16 mg/kg), 1-butaclamol (0.16 mg/kg) and 
clozapine (2.5 mg/kg). 
Following pretreatment with chlorpromazine (10 mg/kg) and 
declamol (0.16 mg/kg), animals were unable to respond due to 
sedation. 
I. Cyclazocine Analgesia - Mouse Tail Flick 
Cyclazocine was tested for analgesia at doses of 2.5 
mg/kg and 5.0 mg/kg. At the smaller dose of cyclazocine, 20% 
.so 
TABLE 14. ANTAGONISM OF MORPHINE DISCRIMINATIVE STIMULUS GENERALIZATION 
TO CYCLAZOCINE (1 . 25 mg/kg) BY NALOXONEl 
Naloxone 
Dose (mg/kg) N 
0 8 
0.08 4 
0.32 6 
1. 25 6 
% 
Selecting 
Morphine 
Lever 
88* 
100* 
33 
0 
Re sponses on Unselected Lever 
Before First Reinforcement 
(Mean + S.E . ) 
Following Drug Following Saline 
Lever Selection Lever Selection 
0 0 
0 No saline selection 
0 0 
No drug selection 0 
1 . Naloxone administered 15 minutes prior to cyclazocine (1.25 mg/kg) 
* Statistically signi f icant difference fp L 0 . 05) by Fisher Exact 
Probability in comparison with 100% saline lever selection (n=l2). 
TABLE 15. GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PRODUCED BY 
MORPHINE (10 mg/kg) TO NON-NARCOrIC PSYCHOACTIVE DRUGS 
Responses on Unselected Lever 
Before First Reinforcement 
% ( Mean + S . E . ) 
Selection 
Morphine Following Drug Following Saline 
Drug Dose N Lever Lever Selection Lever Selection 
d-BUTACLAMOL 0.16 4 0 No drug selection 0 
1-BUTACLAMOL 0.16 6 0 No drug selection 0 
d-AMPHETAMINE 0.64 4 0 No drug selection 0.75+0.75 (4) 
HALOPERIOOL 0.32 8 0 No drug selection 0.63+0.50 ( 8) 
CLONIDINE 0.16 4 25 0 3.00+3.00 ( 3) 
51 
52 
l 
TABLE 16. THE EFFECTS OF HALOPERII:DL PRETREATMENT UPON THE DISCRIMINATE 
STIMULUS PRODUCED BY MORPHINE (10 ~g/kg) 
Responses on Unselected Lever 
Before First Reinforcement 
9o (Mean + S.E.) 
Morphine Selecting 
Halo per idol Dose Morphine Following Drug Following Saline 
Dose (mg/kg) (m.g:/kg ) N Lever Lever Selection Lever Selection 
0 2.50 17 47* 0 5.00 + 1.00 (2) 
0 10.00 12 100* 0 
0.32 2.50 16 13 0 6.00 + 3.01 (2) 
0.32 10.00 7 57 0 1.00 + 0 (1) 
1. Haloperidol administered one hour prior to morphine. 
* Statistically significant difference (p 2_0.05) by Fisher Exact 
Probability in comparison to saline pretreatment. 
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of the animals tested were analgesic at five minutes post in-
jection and 10% were analgesic at 35 minutes post injection 
(n=lO). A dose of 5.0 mg/kg cyclazocine produced analgesia 
in 58% of animals tested five minutes following injection 
and 32% of the animals tested 35 minutes following injection 
(n=l9) (Table 17). 
The analgesic properties of cyclazocine were antagonized 
by the narcotic antagonist, naloxone (10 mg/kg) (Table 17). 
J. The Effects of Neuroleptic Pretreatment Upon Cyclazocine 
Analgesia 
Oxiperomide (0.64 mg/kg), administered one hour 
prior to cyclazocine (2.5 mg/kg), produced a significant in-
crease in the percent animals with analgesic latencies 35 
minutes after cyclazocine injection as compared to groups of 
animals receiving saline pretreatment (Table 18). In saline 
pretreated animals, cyclazocine (2.5 mg/kg) administration in 
20% animals tested having analgesic latencies five minutes 
after cyclazocine while 10% of the animals had analgesic laten~ 
cies after 35 minutes (n=lO). In animals receiving oxipero-
mide (0.64 mg/kg) pretreatment, 89% of the animals had anal-
gesic latencies five minutes after cyclazocine while 100% of 
these animals had analgesic latencies 35 minutes after injec-
tion (n=9). Oxiperomide administered alone does not produce 
analgesia. 
Clozapine (2.5 mg/kg), administered 30 minutes prior to 
cyclazocine (2.5 mg/kg), produced a potentiation of the 
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TABLE 17. 
1 THE EFFECTS OF NALOXONE UPON CYCLAZOCINE ANALGESIA USING 
MOUSE TAIL FLICK PROCEDURE 
Analgesia 2 % 
Naloxone Cyclazocine 
nose (mg/kg) Dose (mg/kg) N 5 Minutes 35 Minutes 
0 2.50 10 20 10 
0 5.00 19 58 32 
10 2.50 10 0 0 
10 5.00 8 0 0 
1. Naloxone administered 10 minutes prior to cyclazocine. 
2. Analgesic latencies exceed group control mean by three standard 
deviations or more. 
TABLE 18. THE EFFECTS OF NEUROLEPTIC PRETREATMENT UPON CYCLAZONE 
ANALGESIA 
% Analgesia 
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1 
Drug Dose (mg/kg) Time (Minutes N 5 Minutes 35 Minutes 
SALINE 60 10 20 10 
OXIPEROMIDE 0.04 60 8 12 38 
0.16 60 8 50 0 
0.64 60 9 89 100* 
HALOPERIDOL 0.04 60 5 40 20 
0.08 60 10 90 60 
0.64 60 14 79 67 
2 .50 60 8 38 75 
DEXCLAMOL 0.04 60 9 44 67 
0.16 60 9 78 44 
PIPAMPERONE 0 .64 60 8 38 38 
2.50 60 10 60 40 
10.00 60 7 72 86* 
CLOZAPINE 0 . 64 30 9 22 11 
1.25 30 10 50 30 
2.50 30 9 67 100* 
HALOPOMIDE 0.16 60 11 36 36 
0.64 60 10 20 40 
1-BUTACLAMOL 0 .16 60 10 40 20 
A CEPERO NE 10.00 60 10 30 30 
1. Analges ic latencies exceed the group control mean by three standard 
deviations or more. 
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analgesic potency of cyclazocine 35 minutes after cyclazocine 
administration (Table 18). Clozapine administered alone does 
not produce analgesia. 
Increases in percent animals with analgesic readings were 
observed following pretreatment with haloperidol (0.08, 0.64, 
and 2.5 mg/kg) and dexclamol (0.16 mg/kg), but these changes 
were not statistically significant (Table 18). 
No change in the analgesic potency of cyclazocine was 
evident following pretreatment with halopomide (0.16 and 0.64 
mg/kg), 1-butaclamol (0.16 mg/kg) or aceperone (10 mg/kg). 
V. DISCUSSION 
In agreement with other recent reports (Hirschhorn, 1977; 
Rosecrans et al., 1978; Teal and Holtzman, 1980), the narcotic 
agonist-antagonist cyclazocine has been shown to produce a dis-
criminative stimulus capable of controlling operant respond-
ing in the rat. The results described indicate that these ef-
fects are specific to cyclazocine and that they are substan-
tially, but not exclusively, based on narcotic-like actions of 
cyclazocine. 
The specificity of the discriminative stimulus produced 
by cyclazocine is demonstrated by the dose dependent nature 
of lever selection in animals trained to discriminate cycla-
zocine from saline. The drug specificity of these effects is 
also seen in the dose dependent nature of generalization of 
the cyclazocine discriminative stimulus to other narcotic 
drugs. 
The discriminative stimulus produced by cyclazocine was 
found to be completely blocked by the pure narcotic antagonist 
naloxone, suggesting that the discriminative stimulus produced 
by cyclazocine is mediated by activity at central opiate re-
ceptors. Cyclazocine discriminative stimulus production at 
central opiate receptors is also suggested by the nature of 
the sti~ulus generalization which were observed in these ex-
periments. Complete generalization of the cyclazocine dis-
criminative stimulus to other narcotic drugs. 
SiJ 
The discriminative stimuJus produced by cyclazocine was 
found to be completely blocked by the pure narcotic antagonist 
naloxone, suggesting that the discriminative stimulus produced 
by cyclazocine is mediated by activity at central opiate re-
ceptors. Cyclazocine discriminative stimulus production at 
central opiate receptors is also suggested by the nature of 
the stimulus generalization which were observed in these ex-
periments. Complete generalization of the cyclazocine discrim-
inative stimulus was observed to all narcotic agonists and an-
tagonists tested with the exception of U-49,274A and U-50,788E 
while generalization testing with non-narcotic psychoactive 
drugs resulted in nearly exclusive saline lever selection. 
Although the central activity of cyclazocine was narcotic 
in nature, certain portions of the results indicate that the 
discriminative stimulus produced by cyclazocine may differ from 
that produced by the pure narcotic agonist morphine. Both the 
cyclazocine discriminative stimulus and the morphine . discrimi-
native stimulus were reversed by the narcotic antagonist 
naloxone. Similarly, generalization of each of these drugs to 
the other was antagonized by naloxone. The dose of naloxone 
required to antagonize the effects of cyclazocine far exceeded 
that required to antagonize morphine. A mechanism for such a 
difference is not readily apparent from the present results 
however it is noteworthy that a similar difference in naloxone 
sensitivity between cyclazocine like drugs and morphine has 
been observed in previous discriminative stimulus studies 
59 
(Hirschhorn, 1977; Rosecrans et al., 1978; Teal and Holtzman, 
1980) and animal behavior studies (Buckett and Shaw, 1975; 
Tepper and Woods, 1978). 
The nature in which cyclazocine and morphine generalized 
to ethylketocyclazocine further suggest a difference in the 
effects produced by cyclazocine and morphine. In the case of 
cyclazocine, ethylketocyclazocine generalization was a uni-
formly increasing dose dependent effect. In the morphine gen-
eralization experiments, it was found that ethylketocyclazo-
cine generalization approximated a bell shaped curbe with the 
highest dose tested resulting in 100% saline lever selection. 
It is apparent that the generalization to ethylketocyclazocine 
by cyclazocine and morphine is different suggesting differ-
ences in central binding characteristics. 
An interesting aspect of the bell shaped morphine gener-
alization to ethylketocyclazocine is that it closely approxi-
mated the nature of the subjective effects produced in humans 
by narcotic agonist-antagonist when compared to morphine. It 
has been shown that human addicts identify low doses of nar-
cotic agonist-antagonists as morphine like while higher doses 
tend to produce effects unlike morphine such as dysphoria and 
hallucinations (Martin et al., 1965). 
Teal and Holtzman (1980) recently showed that the general-
ization of cyclazocine to phencyclidine and ketamine, two non-
opioid drugs, was not subject to naloxone antagonism. The 
present results indicate that the generalization of cyclazocine 
to the narcotic agonist-antagonist nalorphine also is not 
60 
completely antagonized by naloxone. These results suggest that 
a non-narcotic component of the activities of the narcotic ago-
nist-antagonists may be partially responsible for the produc-
tion of their discriminative stimuli and suggests a qualita-
tive difference in the central effects of the pure narcotic 
agonists such as morphine and the narcotic agonist-antagonists 
such as cyclazocine. 
Many of the observed differences between cyclazocine and 
morphine may be explained in terms of a difference in af fini-
ties of these drugs for a single opiate receptor. An alterna-
tive explanation is that the observed differences may be due 
to differential activities at different types of narcotic 
receptors which have recently been described (Martin et al., 
1976; Gilbert and Martin, 1976). Within this system, morphine 
and cyclazocine are proposed to have different affinities and 
activities at three heterogeneous opiate rec~ptors. The pre-
sent results and many other results describing differences 
between cyclazocine and morphine are consistent with a multi-
receptor theory, however, the actual existence of these re-
ceptors has not been substantiated in all species, requiring 
caution in interpreting results in terms of multiple opiate 
receptors. 
A larqe body of literature exists describing the role of 
dopamine in the central activity of narcotic analgesics (for 
review see Lal, 1975). The present results demonstrate that 
dopamine also plays a role in the production of the discrim-
inative stimulus properties of narcotic analgesics. Haloperidol, 
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benperidol and d-butaclamol, neuroleptic druqs with dopamine 
receptor blocking properties, all caused an attenuation of the 
cyclazocine discriminative stimulus while haloperidol also 
blocked the stimulus strength of morphine. Since this effect 
was observed in the stimuli produced by the pure narcotic ago-
nist as well as the narcotic agonist-antagonists, it is 
reasonable to assume that the dopamine activity which is pre-
sent is common to both types of narcotic agents and is not a 
predorninent factor responsible for the observed differences 
between morphine and cyclazocine. 
Although neuroleptic pretreatment caused a diminished 
discriminative stimulus strength of cyclazocine and morphine, 
neuroleptic pretreatment produced a potentiation of cyclazo-
cine analgesia in these experiments. Previous results (Head 
et al., 1979) showed that neuroleptic pretreatment caused a 
potentiation of morphine analgesia. Again, cyclazocine and 
morphine are effected in a similar fashion by neuroleptic pre-
treatment suggesting a similar dopamine role in the central 
activities of each of these drugs. 
The attenuating effects neuroleptics had upon the cyclaz-
ocine and morphine discriminative stimuli when compared with 
the potentiating effects neuroleptics had upon cyclazocine and 
morphine analgesia show that the discriminative ~timuli pro-
duced by these drugs are not based upon the analgesic proper-
ties of these drugs. If in fact the stimulus properties were 
based upon analgesia, one would expect either exclusive poten-
tiation or exclusive attenuation of these properties following 
neuroleptic pretreatment. 
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VI. CONCLUSION 
The experiments which have been described demonstrate 
that the narcotic agonist-antagonist cyclazocine produces 
a discriminative stimulus in the laboratory rat. In light 
of its naloxone reversability and qeneralization to other 
narcntic drugs, it is suggested that the cyclazocine dis-
criminative stimulus is principally produced by activity at 
central opiate receptors. The cyclazocine discriminative 
stimulus was subject to attenuation following neuroleptic 
pretreatment indicating that an additional component of the 
cyclazocine discriminative stimulus is dopa~inergic in na-
ture. 
Similarities between the cyclazocine discriminative 
stimulus and the discriminative stimulus produced by the 
pure narcotic agonist morphine were seen in that the mor-
phine discriminative stimulus was also subject to naloxone 
antasonism and neuroleptic attenuatior.. 
Although the cyclazocine discriwinative stimulus was 
shown to be morphine like as described above, portions of 
the results also indicate that the cyclazocine discrimina-
tive stimulus di f fered from the morphine discri~inative 
stimulus. Cyclazocine was shown to be much less sensitive 
to naloxone antagonism than was morphine. In addition, 
the generalization of cyclazocine and morphine to ethyl-
ketocy clazocine were found to differ markedly. 
6'3 
These experiments have also demonstrated that the cyclazo-
cine discrininative stimulus is not based upon the analgesic 
properties of the drug. While the discriminative stimulus 
was partially blocked by neuroleptic pretreatr'.ent, the anal-
gesic properties of cyclazocine were potentiated by neuro-
leptic pretreatment. In light of previous experimentation 
which denonstrated that morphine analgesia was potentiated 
by haloperidol (Head et al., 1979) ,the present finding of 
haloperidol attenuation of the morphine discriminative stim-
ulus indicates that the morphine discriminative stimulus is 
not based upon the analgesic properties of morphine. 
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